The Effects of Intravenous Immunoglobulins in Women with Recurrent Miscarriages: A Systematic Review of Randomised Trials with Meta-Analyses and Trial Sequential Analyses Including Individual Patient Data
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Immunological disturbances are hypothesised to play a role in recurrent miscarriage (RM) and therefore intravenous immunoglubulins (IVIg) have been tested in RM patients. OBJECTIVES: The objectives were to investigate the benefits and harms of IVIg versus placebo, no intervention, or treatment as usual in women with RM. SEARCH STRATEGY: We searched the published literature in all relevant databases. SELECTION CRITERIA: Randomised trials investigating IVIg versus placebo, no intervention, or treatment as usual in women with RM. DATA COLLECTION AND ANALYSIS: We undertook meta-analyses of aggregated data and individual patient data using a two-step approach, and we conducted bias domain assessments and trial sequential analyses to assess the risks of systematic and random errors. MAIN RESULTS: We identified 11 randomised clinical trials. No significant difference in the frequency of no live birth was found when IVIg was compared with placebo or treatment as usual (RR 0.92, 95% CI 0.75-1.12, p = 0.42). Trial sequential analysis showed that the required information size of 1,008 participants was not obtained. IVIg compared with placebo seems to increase the risk of adverse events. Subgroup analysis suggests that women with RM after a birth (secondary RM) seemed most likely to obtain a potential beneficial effect of IVIg (RR for no live birth 0.77, 95%CI 0.58-1.02, p = 0.06), however, trial sequential analysis showed that insufficient information is presently accrued. CONCLUSION: We cannot recommend or refute IVIg in women with RM. IVIg should therefore be assessed in further randomised clinical trials with positive outcomes before any clinical use is considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538
Self-citationTrial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.013 · Cited by 1,881
Self-citationIndustry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Rai, R., & Regan, L. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69204-0 · Cited by 1,227
Savović, J., Jones, H. E., Altman, D. G., Harris, R. J., Jüni, P., Pildal, J., Als-Nielsen, B., Balk, E. M., Gluud, C., Gluud, L. L., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-6-201209180-00537 · Cited by 1,049
Self-citationSavović, J., Jones, H., Altman, D., Harris, R., Jűni, P., Pildal, J., Als-Nielsen, B., Balk, E., Gluud, C., Gluud, L., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16350 · Cited by 668
Self-citationIndustry sponsorship and research outcome
Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O. A., & Bero, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub2 · Cited by 605
Immunotherapy for recurrent miscarriage
Wong, L. F., Porter, T. F., & Scott, J. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000112.pub3 · Cited by 348
Cited by
ESHRE guideline: recurrent pregnancy loss
The ESHRE Guideline Group on RPL, Bender Atik, R., Christiansen, O. B., Elson, J., Kolte, A. M., Lewis, S., Middeldorp, S., Nelen, W., Peramo, B., Quenby, S., et al. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy004 · Cited by 1,002
Self-citationDimitriadis, E., Menkhorst, E., Saito, S., Kutteh, W. H., & Brosens, J. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00228-z · Cited by 702
Recurrent pregnancy loss: current perspectives
El Hachem, H., Crepaux, V., May-Panloup, P., Descamps, P., Legendre, G., & Bouet, P.-E. (2017) · International Journal of Women's Health · doi:10.2147/ijwh.s100817 · Cited by 462
Toth, B., Würfel, W., Bohlmann, M., Zschocke, J., Rudnik-Schöneborn, S., Nawroth, F., Schleußner, E., Rogenhofer, N., Wischmann, T., von Wolff, M., et al. (2018) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0586-4568 · Cited by 119
“A recent meta-analysis which included 11 randomized studies of the type described above found no significantly higher LBR for the group of patients who received IVIG (RR 0.92; 95% CI: 0.75 – 1.12) compared to placebo or standard care [101].”
InfluentialImmunological Risk Factors in Recurrent Pregnancy Loss: Guidelines Versus Current State of the Art
Vomstein, K., Feil, K., Strobel, L., Aulitzky, A., Hofer-Tollinger, S., Kuon, R.-J., & Toth, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040869 · Cited by 113
Metadata
- Authors
- Egerup, P., Lindschou, J., Gluud, C., Christiansen, O. B., & ImmuReM IPD Study Group
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-10-30
- Volume
- 10
- Issue
- 10
- Pages
- e0141588
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1939569932
- Cited by
- 65
- References
- 9
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.